(Q40856126)

24 September 2017

Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group (English)

1 reference

24 September 2017

0 references

1 reference

Laudadio C

1

1 reference

PubMed ID

9618066

24 September 2017

Sima AA

series ordinal

2

1 reference

24 September 2017

1 May 1998

1 reference

Journal of Diabetes and its Complications

24 September 2017

1 reference

24 September 2017

12

1 reference

24 September 2017

3

1 reference

24 September 2017

121-127

1 reference

The effects of age and diabetes mellitus on nerve function

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Autonomic neural dysfunction in recently diagnosed diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Aldose reductase inhibition improves nerve conduction velocity in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Effects of aldose reductase inhibitors on the progression of nerve damage

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900074-3

7 January 2021

10.1016/S1056-8727(97)00074-3

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9618066